Benzinga Pro data, FibroGen (NASDAQ:FGEN) reported Q1 sales of $36.16 million. Earnings fell to a loss of $76.70 million, resulting in a 15.91% decrease from last quarter. In Q4, FibroGen brought in $34.37 million in sales but lost $66.17 million in earnings.

What Is Return On Invested Capital?

Return on Invested Capital is a measure of yearly pre-tax profit relative to capital invested by a business. Changes in earnings and sales indicate shifts in a company's ROIC. A higher ROIC is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROIC suggests the opposite. In Q1, FibroGen posted an ROIC of 155.76%.

Keep in mind, while ROIC is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

For FibroGen, the positive return on invested capital ratio of 155.76% suggests that management is allocating their capital effectively. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns.

Upcoming Earnings Estimate

FibroGen reported Q1 earnings per share at $-0.81/share, which did not meet analyst predictions of $-0.75/share.

This article was generated by Benzinga's automated content engine and reviewed by an editor.